(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2013 (10.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/006675 A1

(51) **International Patent Classification**:
C07K 14/435 (2006.01) *C12N 5/00* (2006.01)

(21) **International Application Number**:
PCT/US2012/045505

(22) **International Filing Date**:
5 July 2012 (05.07.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/504,406	5 July 2011 (05.07.2011)	US
11174267.2	15 July 2011 (15.07.2011)	EP

(71) **Applicants** *(for all designated States except US)*: **NOVOZYMES BIOPHARMA UK LIMITED** [GB/GB]; Castle Court, 59 Castle Boulevard, Nottingham Nottinghamshire NG7 1FD (GB). **NOVOZYMES BIOPHARMA AU LIMITED** [AU/AU]; 28 Dalgleish Street, Thebarton, South Australia SA 5031 (AU). **NOVOZYMES BIOPHARMA US, INC.** [US/US]; One Broadway 14th Floor, Cambridge, Massachusetts 02142 (US). **NOVOZYMES BIOPHARMA DK A/S** [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **MERKEL, Sandra Marie** [US/US]; 5317 North Hills Drive, Raleigh, North Carolina 27612 (US). **DIMASI, Luke** [AU/US]; 6 Union Park, Apt. 1, Boston, Massachusetts 02118 (US). **SHEAHAN, Collette Ann** [AU/AU]; 20 Craigie Street, Birkenhead, South Australia 5015 (AU). **MORTON, Phillip Harvey** [GB/GB]; 9 Trevor Road, West Brigford, Nottingham Nottinghamshire NG2 6FS (GB).

(74) **Agents**: **LAMBIRIS, Elias J.** et al.; Novozymes North America, Inc., 60 East 42nd Street, Suite 700, New York, New York 10165 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/006675 A1

(54) **Title**: ALBUMIN FORMULATION AND USE

(57) **Abstract**: The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.